Abscorbic acid commonly known as Vitamin C is a water-soluble vitamin, which is necessary in the body to form collagen in bones, cartilage, muscle, and blood vessels and aids in the absorption of iron. Dietary sources of vitamin C include fruits and vegetables, particularly citrus fruits such as oranges.
Severe deficiency of vitamin C causes scurvy. Although rare, scurvy includes potentially severe consequences, and can cause sudden death. Patients with scurvy are treated with vitamin C and should be under medical supervision.
Many uses for vitamin C have been proposed, but few have been found to be beneficial in scientific studies. In particular, research in asthma, cancer, and diabetes remains inconclusive, and no benefits have been found in the prevention of cataracts or heart disease.
The Epstein-Barr virus (EBV) is a member of the herpes family that targets lymphocytes and epithelial cells. While the infection is usually benign, it can in some cases lead to acute infectious mononucleosis and can impair the immune system. EBV is also linked to several malignancies. There is currently no cure for removing EBV infections and very little success treating acute EBV infection and mononucleosis with drugs.
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.
Researchers working at the University of Saskatchewan have discovered new potential in prairie fruits, in particular, buffaloberry, chokecherry and sea buckthorn, according to a new study published today in the Canadian Journal of Plant Science.
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism.
Researchers have created a new type of biosensor that can detect minute concentrations of glucose in saliva, tears and urine and might be manufactured at low cost because it does not require many processing steps to produce.
Scientists have found a way to replace up to 50 per cent of chocolate's fat content with fruit juice.
Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.
Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?
Vitamin C supplementation in pregnant women who are unable to quit smoking significantly improves pulmonary function in their newborns, according to a new study.
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.
They look like fruit, and indeed the nanoscale stars of new research at Rice University have tasty implications for medical imaging and chemical sensing.
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.
Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.
Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.
It would appear that in terms of composition, the intestinal bacteria of every individual can be divided into three main groups known as enterotypes. The intestinal bacteria in each enterotype organise themselves into distinct, stable clusters displaying common features.
Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.
Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.
Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
A study conducted at the University of Granada and at the University Hospital San Cecilio revealed that preterm mothers' milk contains low concentrations of coenzyme Q10. This is a complex of great medical importance, due both to its antioxidant capacity and to its role as a component of the electron transport chain, among other functions.
Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.